Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Payables: 2009-2025

Historic Payables for Aytu Biopharma (AYTU) over the last 15 years, with Sep 2025 value amounting to $12.3 million.

  • Aytu Biopharma's Payables fell 30.60% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.7 million, marking a year-over-year decrease of 6.20%. This contributed to the annual value of $10.6 million for FY2025, which is 16.59% down from last year.
  • As of Q3 2025, Aytu Biopharma's Payables stood at $12.3 million, which was up 16.42% from $10.6 million recorded in Q2 2025.
  • Aytu Biopharma's 5-year Payables high stood at $25.1 million for Q1 2023, and its period low was $9.4 million during Q3 2021.
  • Its 3-year average for Payables is $14.6 million, with a median of $12.7 million in 2024.
  • Its Payables has fluctuated over the past 5 years, first soared by 125.30% in 2023, then plummeted by 51.92% in 2024.
  • Aytu Biopharma's Payables (Quarterly) stood at $15.6 million in 2021, then grew by 15.41% to $18.0 million in 2022, then plummeted by 36.15% to $11.5 million in 2023, then skyrocketed by 36.63% to $15.7 million in 2024, then crashed by 30.60% to $12.3 million in 2025.
  • Its Payables stands at $12.3 million for Q3 2025, versus $10.6 million for Q2 2025 and $12.0 million for Q1 2025.